Clinical Trial Update: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PQR309 in relapsed or refractory primary central nervous system lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• PQR309

Snippet

Sponsor: PIQUR Therapeutics AG | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: COMPLETED